NRSN Latest Press Releases

-- October 19, 2026 --

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury PRNewswire 8:26 AM

-- October 13, 2026 --

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones PRNewswire 8:31 AM

-- October 2, 2026 --

NeuroSense Provides Update on Nasdaq Listing Compliance PRNewswire 4:15 PM

-- September 28, 2026 --

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference PRNewswire 12:44 PM

-- September 25, 2026 --

NeuroSense Provides Business Update and Progress for the First Half of 2026 PRNewswire 4:30 PM

-- September 10, 2026 --

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference PRNewswire 9:00 AM

-- August 31, 2026 --

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS PRNewswire 8:45 AM

-- August 13, 2026 --

NeuroSense Issues CEO Letter to Shareholders PRNewswire 9:32 AM

-- August 6, 2026 --

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PRNewswire 11:30 AM

-- July 22, 2026 --

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS PRNewswire 8:30 AM

-- July 6, 2026 --

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PRNewswire 8:45 AM

-- June 29, 2026 --

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS PRNewswire 9:30 AM

-- June 25, 2026 --

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PRNewswire 9:20 AM

-- June 22, 2026 --

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PRNewswire 9:00 AM

-- June 11, 2026 --

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS PRNewswire 9:00 AM

-- June 9, 2026 --

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition PRNewswire 9:00 AM

Market Data Delayed 15 Minutes